Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial

Abstract

BackgroundThe treatment results of external beam radiotherapy for intermediate and high risk prostate cancer patients are insufficient with five-year biochemical relapse rates of approximately 35%. Several randomized trials have shown that dose escalation to the entire prostate improves biochemical disease free survival. However, further dose escalation to the whole gland is limited due to an unacceptable high risk of acute and late toxicity. Moreover, local recurrences often originate at the location of the macroscopic tumor, so boosting the radiation dose at the macroscopic tumor within the prostate might increase local control. A reduction of distant metastases and improved survival can be expected by reducing local failure. The aim of this study is to investigate the benefit of an ablative microboost to the macroscopic tumor within the prostate in patients treated with external beam radiotherapy for prostate cancer.Methods/DesignThe FLAME-trial (Focal Lesion Ablative Microboost in prostatE cancer) is a single blind randomized controlled phase III trial. We aim to include 566 patients (283 per treatment arm) with intermediate or high risk adenocarcinoma of the prostate who are scheduled for external beam radiotherapy using fiducial markers for position verification. With this number of patients, the expected increase in five-year freedom from biochemical failure rate of 10% can be detected with a power of 80%. Patients allocated to the standard arm receive a dose of 77 Gy in 35 fractions to the entire prostate and patients in the experimental arm receive 77 Gy to the entire prostate and an additional integrated microboost to the macroscopic tumor of 95 Gy in 35 fractions. The secondary outcome measures include treatment-related toxicity, quality of life and disease-specific survival. Furthermore, by localizing the recurrent tumors within the prostate during follow-up and correlating this with the delivered dose, we can obtain accurate dose-effect information for both the macroscopic tumor and subclinical disease in prostate cancer. The rationale, study design and the first 50 patients included are described.Trial registrationThis study is registered at ClinicalTrials.gov: NCT01168479

Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation

“…A boost to the largest lesion in the prostate (the dominant lesion), in addition to a standard dose to the whole organ may achieve adequate dose escalation without increasing toxicity [4,5]. This hypothesis is currently tested in a phase III clinical trial, the FLAME trial [6]. Boost volumes can be defined on multiparametric magnetic resonance imaging (mp-MRI).…”

Abiraterone and Volumetric Modulated Arc Therapy for Second Recurrence of Node-Positive Prostate Cancer – A Case Repo

“…This is compared to conventional dose EBRT for the whole prostate gland without guidance for PTV by imaging from MRI or PET/CT scanning [18].…”

Evolution of advanced technologies in prostate cancer radiotherapy

“…Tsuji et al 94 122 With respect to treatment delivery, the 2D, 3D and 4D IGRT systems discussed in this Review are generally used to improve accuracy and precision of radiotherapy by helping to reduce treatment margins. However, some evidence suggests that extreme reduction of margins negatively affects outcome.…”